Patents by Inventor Richard B. S. Roden

Richard B. S. Roden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230242488
    Abstract: The invention of the instant application discloses spirocyclic guanidine compounds of general formula (I), shown below, and their use in methods of treating cancer
    Type: Application
    Filed: May 18, 2021
    Publication date: August 3, 2023
    Applicant: The Johns Hopkins University
    Inventors: Richard B.S. Roden, Ravi K. Anchoori
  • Publication number: 20230045142
    Abstract: Compounds of formula (I), (II), and (III) having the structure shown below are presented: wherein R-R6 are defined herein.
    Type: Application
    Filed: December 4, 2020
    Publication date: February 9, 2023
    Applicant: The Johns Hopkins University
    Inventors: Richard B.S. Roden, Ravi K. Anchoori
  • Patent number: 10046026
    Abstract: This invention relates, e.g., to a virus-like particle (VLP) composition assembled from a chimeric polypeptide comprising a papilloma virus (e.g., human papillomavirus, or HPV) L1 major capsid protein, into which is inserted a surface-displayed peptide comprising a neutralizing epitope of a papillomavirus L2 protein. Vaccine compositions comprising the VLP are described, as well as methods for inducing an immune response (e.g., vaccinating) a subject against papilloma virus, using the VLP, and kits comprising the VLP, for carrying out a method of the invention.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: August 14, 2018
    Assignee: The Johns Hopkins University
    Inventors: Richard B. S. Roden, Reinhard Kirnbauer, Christina Schellenbacher
  • Publication number: 20160200774
    Abstract: This invention relates, e.g., to a virus-like particle (VLP) composition assembled from a chimeric polypeptide comprising a papilloma virus (e.g., human papillomavirus, or HPV) L1 major capsid protein, into which is inserted a surface-displayed peptide comprising a neutralizing epitope of a papillomavirus L2 protein. Vaccine compositions comprising the VLP are described, as well as methods for inducing an immune response (e.g., vaccinating) a subject against papilloma virus, using the VLP, and kits comprising the VLP, for carrying out a method of the invention.
    Type: Application
    Filed: October 5, 2015
    Publication date: July 14, 2016
    Inventors: Richard B.S. Roden, Reinhard Kirnbauer, Christina Schellenbacher
  • Patent number: 9388221
    Abstract: The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein o
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: July 12, 2016
    Assignees: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, The Johns Hopkins University
    Inventors: John T. Schiller, Diana V. Pastrana, Richard B. S. Roden, Ratish Gambhira, Douglas R. Lowy
  • Patent number: 9149503
    Abstract: This invention relates, e.g., to a virus-like particle (VLP) composition assembled from a chimeric polypeptide comprising a papilloma virus (e.g., human papillomavirus, or HPV) L1 major capsid protein, into which is inserted a surface-displayed peptide comprising a neutralizing epitope of a papillomavirus L2 protein. Vaccine compositions comprising the VLP are described, as well as methods for inducing an immune response (e.g., vaccinating) a subject against papilloma virus, using the VLP, and kits comprising the VLP, for carrying out a method of the invention.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: October 6, 2015
    Assignee: The Johns Hopkins University
    Inventors: Richard B. S. Roden, Reinhard Kirnbauer, Christina Schellenbacher
  • Patent number: 9138470
    Abstract: Embodiments of the invention are directed to methods and compositions for generating an antibody response against HPV epitopes using multi-component vaccines. One such multi-component vaccine requires a T cell helper component and a toll-like receptor (TLR) agonist. In one embodiment, the inventors described a lipopeptide composition comprising an HPV L2 epitope.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: September 22, 2015
    Assignee: The Johns Hopkins University
    Inventors: Richard B. S. Roden, Ratish Gambhira, Hannah H. Alphs
  • Publication number: 20140294890
    Abstract: Recombinant adenovirus vaccines comprising recombinant adenoviruses whose hexon, fiber or protein IX capsid proteins are engineered to include exogenous peptide segments, e.g. vaccines for human papillomavirus (HPV) and malaria.
    Type: Application
    Filed: July 19, 2013
    Publication date: October 2, 2014
    Applicant: The Johns Hopkins University
    Inventors: Gary W. Ketner, Richard B.S. Roden, Fidel P. Zavala
  • Publication number: 20130177585
    Abstract: The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein o
    Type: Application
    Filed: February 21, 2013
    Publication date: July 11, 2013
    Inventors: John T. Schiller, Diana V. Pastrana, Richard B.S. Roden, Ratish Gambhira, Douglas R. Lowy
  • Patent number: 8404244
    Abstract: The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein o
    Type: Grant
    Filed: February 1, 2006
    Date of Patent: March 26, 2013
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Johns Hopkins University
    Inventors: John T. Schiller, Diana V. Pastrana, Richard B. S. Roden, Ratish Gambhira, Douglas R. Lowy
  • Publication number: 20120093821
    Abstract: This invention relates, e.g., to a virus-like particle (VLP) composition assembled from a chimeric polypeptide comprising a papilloma virus (e.g., human papillomavirus, or HPV) L1 major capsid protein, into which is inserted a surface-displayed peptide comprising a neutralizing epitope of a papillomavirus L2 protein. Vaccine compositions comprising the VLP are described, as well as methods for inducing an immune response (e.g., vaccinating) a subject against papilloma virus, using the VLP, and kits comprising the VLP, for carrying out a method of the invention.
    Type: Application
    Filed: April 12, 2010
    Publication date: April 19, 2012
    Applicant: The John Hopkins University
    Inventors: Richard B. S. Roden, Reinhard Kirnbauer, Christina Schellenbacher
  • Publication number: 20110177112
    Abstract: Embodiments of the invention are directed to methods and compositions for generating an antibody response against HPV epitopes using multi-component vaccines. One such multi-component vaccine requires a T cell helper component and a toll-like receptor (TLR) agonist. In one embodiment, the inventors described a lipopeptide composition comprising an HPV L2 epitope.
    Type: Application
    Filed: November 3, 2008
    Publication date: July 21, 2011
    Applicant: The Johns Hopkins University
    Inventors: Richard B. S. Roden, Ratish Gambhira, Hannah H. Alphs
  • Publication number: 20090047301
    Abstract: The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein o
    Type: Application
    Filed: February 1, 2006
    Publication date: February 19, 2009
    Applicant: The Johns Hopkins University
    Inventors: John T. Schiller, Diana V. Pastrana, Richard B.S. Roden, Ratish Gambhira, Douglas R. Lowy